PRINCETON, N.J., July 16 BioWa, Inc. and Medarex,Inc. (Nasdaq: MEDX) announced today that they have entered into a licenseagreement which provides Medarex with the first ever access to BioWa'sCOMPLEGENT(TM) Technology for enhancing the complement-dependent cytotoxicity(CDC) of select Medarex therapeutic antibodies.
The license grants Medarex non-exclusive rights to research, develop andcommercialize therapeutic antibodies based on COMPLEGENT(TM) Technology for anundisclosed number of targets. In return, BioWa will receive upfront payment,license fees, development milestone payments and royalties on products. Otherdetails of the agreement are not disclosed.
"We are very pleased to announce this new partnership with Medarex, who isalso our first partner for POTELLIGENT(R) Technology," commented Dr. MasamichiKoike, President and CEO of BioWa. "This collaboration with Medarex greatlyhelps us explore the potential of COMPLEGENT(TM) Technology for antibody-basedtherapies."
"We are excited about the possibility of enhancing our antibodies withBioWa's technology platform," said Howard H. Pien, President and CEO ofMedarex. "Our partnership grants Medarex the first access to COMPLEGENT(TM)Technology and we look forward to investigating its potential as we continueto advance our pipeline."
About COMPLEGENT(TM) Technology
COMPLEGENT(TM) Technology is a new technology developed by Kyowa HakkoKogyo Co., Ltd. that enhances one of the major mechanisms of action of anantibody, CDC. With an approach called isotype chimerism, in which portionsof IgG3, an antibody's isotype, are introduced into corresponding regions ofIgG1, the standard isotype for therapeutic antibodies, COMPLEGENT(TM)Technology significantly enhances CDC activity beyond that of either IgG1 orIgG3, while retaining the desirable features of IgG1, such as ADCC, PK profileand Protein A binding. In addition, it can be used together withPOTELLIGENT(R) Technology, creating an even superior therapeutic Mab(AccretaMab(TM)) with enhanced ADCC and CDC activities.
About BioWa, Inc.
BioWa is a wholly owned subsidiary of Kyowa Hakko Kogyo Co., Ltd.(TSE: 4151), Japan's leading pharmaceutical and largest biotech company, andis the exclusive worldwide licensor of AccretaMab(TM) platform.AccretaMab(TM) platform consists of POTELLIGENT(R) and COMPLEGENT(TM)Technologies, creating a superior antibody molecule with enhanced ADCC and CDCactivities. BioWa is offering POTELLIGENT(R) and COMPLEGENT(TM) Technologiesto partners under a license to maximize the value of these technologies.Together with Kyowa, BioWa is focused on development of ADCC/CDC enhancedmonoclonal antibody-based therapeutics to fight cancer and otherlife-threatening and debilitating diseases. For more information about BioWa,visit its web site at www.biowa.com.
POTELLIGENT(R), COMPLEGENT(TM), and AccretaMab(TM) are the trademarks ofKyowa Hakko Kogyo Co., Ltd. All rights are reserved.
Medarex is a biopharmaceutical company focused on the discovery,development and potential commercialization of fully human antibody-basedtherapeutics to treat life-threatening and debilitating diseases, includingcancer, inflammation, autoimmune disorders and infectious diseases. Medarexapplies its UltiMAb(R) technology and product development and clinicalmanufacturing experience to generate, support and potentially commercialize abroad range of fully human antibody product candidates for itself and itspartners. More than 40 of these therapeutic product candidates derived fromMedarex technology are in human clinical testing or have had INDs submittedfor such trials, with seven of the most advanced product candidates currentlyin Phase 3 clinical trials or the subject of regulatory applications formarketing authorization. Medarex is committed to building value by developinga diverse pipeli